Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

290

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: natalizumab IV
DRUG: natalizumab SC
DRUG: IV Placebo
DRUG: SC Placebo

Sponsor

Biogen